SAR
8
0
0
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
12.5%
1 terminated out of 8 trials
80.0%
-6.5% vs benchmark
50%
4 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (8)
A Prospective Study of Stapokibart Injection in Patients With Seasonal Allergic Rhinitis (SAR)
A Phase III Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis
CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas
Efficacy of Vitamin D Treatment in Mortality Reduction Due to COVID-19.
(CBDRA60) to Prevent or Reduce Symptoms of COVID-19 and Prevention of Post-Acute Sequelae of SARS-CoV-2 Infection PASC
Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients
Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine HCl Syrup vs. Loratadine Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR)
Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies